Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy

Cited by (186)

Items 101–186 of 186

1. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
   Ji Hyun Park, Gun Lyung You, Myung‐Ju Ahn, Sang-We Kim, Min Hee Hong, Ji‐Youn Han, Chan-Young Ock, Jong-Seok Lee, In‐Jae Oh, Shin Yup Lee et al. · 2021 · Journal of Cancer Research and Clinical Oncology
2. Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
   Kang Miao, Yan Xu, Wenshuai Xu, Ying Zhang, Yongjian Xu, Xinlun Tian, Li Zhang · 2021 · Thoracic Cancer
3. Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis
   Wenyi Yu, Yukun He, Ying Shang, Tiantian Guo, Keqiang Wang, Hongge Liang, Jianbo Xue, Xinqian Ma, Xinlin Mu, Ran Li et al. · 2023 · Clinical Immunology
4. The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review
   Jixin Chen, Shuqi Chen, Hui Luo, Shunqin Long, Xiaobing Yang, Wenfeng He, Wanyin Wu, Sumei Wang · 2023 · International Immunopharmacology
5. Risk factors for immune-related adverse effects during CPI therapy in patients with head and neck malignancies – a single center study
   Frederic Jungbauer, Annette Affolter, Christoph Brochhausen, Anne Lammert, Sonja Ludwig, Kirsten Merx, Nicole Rotter, Lena Huber · 2024 · Frontiers in Oncology
6. Impact of pneumonitis from radiotherapy combined with immune checkpoint inhibitors therapy on tumor progression and survival in patients with non-small cell lung cancer
   Ziwei Wang, Kunpeng Xu, Han Sun, Jun Liang, Wei Jiang, Lühua Wang · 2025 · Frontiers in Immunology
7. Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study
   Umair Mahmood, Eleni Josephides, Meenali M. Chitnis, Michael Skwarski, Spyridon Gennatas, Sharmistha Ghosh, James F. Spicer, Eleni M. Karapanagiotou, Tanya Ahmad, Martin David Forster et al. · 2025 · Cancers
8. Immune-Related Pneumonitis Was Decreased by Addition of Chemotherapy with PD-1/L1 Inhibitors: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTs)
   Yi-Xiu Long, Yue Sun, Rui-Zhi Liu, Ming-Yi Zhang, Jing Zhao, Yu-Qing Wang, Yu-Wen Zhou, Ke Cheng, Ye Chen, Cai-Rong Zhu et al. · 2022 · Current Oncology
9. Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
   Huixia Li, Yifan Zheng, Peihang Xu, Zimu Li, Yukun Kuang, Xiaoqing Feng, Junhao He, Jia Li, Xiao Chen, Lihong Bai et al. · 2023 · Frontiers in Pharmacology
10. A Real‐Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune‐Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab
    Atsuto Mouri, Hisao Imai, Satoshi Endo, Junichi Nakagawa, Kasumi Tsukamoto, Yuhei Kurata, Ou Yamaguchi, Kenji Masaki, Kosuke Hashimoto, Ayako Shiono et al. · 2025 · Cancer Medicine
11. Predictive value of serum high‐mobility group box 1 levels for checkpoint inhibitor pneumonitis
    Hiroki Tanahashi, Kakuhiro Yamaguchi, Koji Kurose, Satoshi Nakao, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Shintaro Miyamoto, Taku Nakashima, Hiroshi Iwamoto et al. · 2022 · Respirology
12. Clinical Characteristics and Management of Checkpoint Inhibitor Pneumonitis in Non–Small-Cell Lung Cancer Patients After Neoadjuvant Immunotherapy
    Long Jiang, Shanshan Jiang, Wang Miao, Yaofeng Shen, Л. В. Болотина, Hongda Zhu, Ningyuan Zou, Yu Tian, Hanbo Pan, Jia Huang et al. · 2024 · Clinical Lung Cancer
13. Restricted Mean Survival Time—Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?
    Cristina-Florina Pîrlog, Raluca Simona Costache, Andreea Ioana Paroșanu, Cristina Orlov Slavu, Mihaela Olaru, Ana Maria Popa, Cristian Ion Iaciu, Irina Niță, Pompilia Motatu, Horia Teodor Cotan et al. · 2023 · Diagnostics
14. Integrative analysis of single-cell and bulk RNA-sequencing data revealed T cell marker genes based molecular sub-types and a prognostic signature in lung adenocarcinoma
    Yue-Ling Peng, Yafang Dong, Qihui Sun, Yue Zhang, Xiangyang Zhou, Xiaoyang Li, Yuehong Ma, Xingwei Liu, Rongshan Li, Fengjie Guo et al. · 2024 · Scientific Reports
15. Practice Changes in Checkpoint Inhibitor-Induced Immune-Related Adverse Event Management at a Tertiary Care Center
    Malek Shatila, Farzin Eshaghi, Austin R. Thomas, Andrew Kuang, Jay Sanjay Shah, Brandon Zhao, Sidra Naz, Mianen Sun, Sarah Fayle, Jeff Jin et al. · 2024 · Cancers
16. Is the onset of adverse effects of immunotherapy always bad news for the patients…?—certainly not!
    Paul M Hofman · 2019 · Annals of Translational Medicine
17. Nomogram-based prediction of checkpoint inhibitor pneumonitis in lung cancer patients
    Dan Tao, Haike Lei, Lisi Sun, Lulu Wang, Wei Zhou, Ying Wang, Yongzhong Wu · 2026 · BMC Cancer
18. Enrichment of prevotella melaninogenica in the lower respiratory tract links to checkpoint inhibitor pneumonitis and radiation pneumonitis
    Jiajun Chen, Qiong Xu, Liyan Zhang, Donglei Zhang, Xueling Wu · 2025 · Frontiers in Cellular and Infection Microbiology
19. Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients?
    Ziqi Ye, Shiyu Zheng, Jie Chen, Yanfang Zhang, Sihyung Yang, Yun Hong, Hongyu Yang, Zixue Xuan, Qingwei David Zhao · 2022 · International Immunopharmacology
20. Cardiothoracic complications of immune checkpoint inhibitors
    Babina Gosangi, Yifan Wang, Ami N. Rubinowitz, Jennifer M. Kwan, Leah Traube, Christopher Gange, Anna Shlionsky Bader · 2023 · Clinical Imaging
21. Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
    Yuhei Kinehara, Takayuki Shiroyama, Akihiro Tamiya, Motohiro Tamiya, Seigo Minami, Masaki Kanazu, Osamu Morimura, Toshie Niki, Satoshi Tetsumoto, Yoshihiko Taniguchi et al. · 2023 · JTO Clinical and Research Reports
22. Are Immune Checkpoint Inhibitors Safe and Effective in Lung Cancer Patients with Pre-Existing Interstitial Lung Disease?
    Lin Zhu, Rong Gao, Li Han, Yahui Zheng, Junling Yang · 2024 · Immunotherapy
23. Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
    Hidetoshi Hayashi, Makoto Nishio, Hiroaki Akamatsu, Yasushi Goto, Satoru Miura, Akihiko Gemma, Ichiro Yoshino, Toshihiro Misumi, Takashi Kijima, Naoto Takase et al. · 2024 · Cancer Research Communications
24. Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors
    Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Pranav M. Patel, Yoshito Zamami, Aya Fukuma Ozaki · 2025 · Cardio-Oncology
25. Immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer patients with preexisting pulmonary emphysema or interstitial lung abnormalities
    Xi Dawn Chen, Caijuan Huan, Piao Yang, Mengye He, Ruiping Wang, Jianying Zhou, Jianya Zhou · 2025 · Lung Cancer
26. Impact of proton pump inhibitor use on immune-related adverse events in patients with non-small cell lung cancer: a retrospective study
    Ippei Miyamoto, Tetsuo Shimizu, Mizuki Hanamura, Ryoma Tanaka, Ryo Kusahana, Masayuki Nomoto, Kenichi Sugaya, Yoshiko Nakagawa, Yasuhiro Gon · 2026 · BMC Cancer
27. Immuncheckpoint-Inhibitor-assoziierte Pneumonitiden
    Anne Bettina Beeskow, Rebecca Mura, Daria Kifjak, Maria Sanzharovskaya, Helmut Prosch · 2026 · Die Radiologie
28. Baseline Neutrophil‐To‐Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non‐Small Cell Lung Cancer: A Two‐Cohort Study With Retrospective Discovery and Prospective Validation
    Tetsu Hirakawa, Kakuhiro Yamaguchi, Shun Takao, Nobuhiro Kanaji, Naoko Matsumoto, Kozue Miyazaki, Tamio Okimoto, Chihiro Ando, Hisao Higo, Masaaki Yanai et al. · 2026 · Respirology
29. Treatment patterns and outcomes of high-grade immune checkpoint inhibitor-related pneumonitis in an oncology hospitalist service
    Joanna-Grace Mayo Manzano, Hadeel Neamat Sahar, Jeffrey D. Aldrich, Maggie Lu, Mahran Shoukier, Christine B. Peterson, Kodwo Bosomefi Dickson, Kwame Koom‐Dadzie, Ed Kheder, Maria Cecilia Franco-Vega et al. · 2024 · Supportive Care in Cancer
30. Complications of immuno‐oncology care: what urologist should know
    Valentina Grajales, Alberto Martini, Neal D. Shore · 2024 · British Journal of Urology
31. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC
    Yiran Rong, Sujith Ramachandran, Kaustuv Bhattacharya, Yi Yang, Sally R. Earl, Yunhee Chang, John P. Bentley · 2024 · Immunotherapy
32. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis
    Won Jin Jeon, Jasmine Nguyen, Dani Ran Castillo, Kiwon Park, Joel M. Brothers, Anthony Nguyen, Hamid Mirshahidi · 2023 · Journal of Oncology Pharmacy Practice
33. The results of quantitative evaluation of postradiation changes in lung cancer patients, which were obtained using a new procedure for analysis of dynamic X-ray computed tomography imaging of thoracic organs
    V. V. Ledenev, Н. В. Нуднов, Vladimir M. Sotnikov, Daria V. Baryshnikova · 2020 · Journal of radiology and nuclear medicine
34. The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)
    Kakuhiro Yamaguchi, Shun Takao, Nobuhiro Kanaji, Tetsu Hirakawa, Naoko Matsumoto, Kozue Miyazaki, Tamio Okimoto, Chihiro Ando, Hisao Higo, Masaaki Yanai et al. · 2025 · European Journal of Cancer
35. Cured but breathless: the growing burden of DIILD in cancer survivors
    Jingxing Li, Wen‐Chien Cheng · 2025 · Nature Reviews Clinical Oncology
36. Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor–related pneumonitis in lung cancer patients
    Friederike Völter, Lukas Wehlte, Blerina Resuli, Julia Walter, Lea Daisenberger, Maria Ingenerf, Maurice M. Heimer, Matthias Brendel, Gabriel Tobias Sheikh, Lena Maria Unterrainer et al. · 2025 · Frontiers in Oncology
37. Impact of Emphysema on Therapeutic Efficacy and Immune-Related Pneumonitis Risk in NSCLC Patients Receiving ICIs: A Meta-Analysis of Improved Survival but Increased Toxicity
    Wenjun Li, Shilan Liu, Xiaodan Yu, Wenyi Lan, Xiao Liu · 2026 · International Journal of COPD
38. Clinical characteristics, prognostic factors, and feasibility of ICI continuation in immune checkpoint inhibitor-related pneumonitis
    Keisuke Masumoto, Kazuya Tsubouchi, Ryosuke Matsukane, Sai Yasukochi, Hiroaki Ogata, Tomotsugu Takano, Mayako Uchida, Isamu Okamoto · 2026 · Cancer Immunology Immunotherapy
39. Pulmonary toxicity of immune checkpoint inhibitors
    Sean Garvey, Parthiban Nadarajan · 2026 · Breathe
40. A review of deep learning-based multimodal data integration of lung cancer
    Ya Qin, Simin Wang, Dan Wu, Yanhua Fei, Weiping Ding, Qiong Wang, Runwei Guan, Xiao Liang · 2026 · Clinical and Experimental Medicine
41. Single-cell profiling unveils an exhaustion trajectory of ZNF683hi tissue-resident alveolar CD8+ T cells in checkpoint inhibitor pneumonitis
    X Y Zhou, Ziming Jiang, Yanhong Ren, Yunzhi Zhou, Lei Deng, Zhenting Liu, Sijin Sun, Jieli Zhang, W.T. Liu, Yi Yang et al. · 2026 · Med
42. Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
    Kinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, Tomoki Kuge, Akito Miyazaki, Kiyohide Komuta, Motohiro Tamiya, Kazumi Nishino, Akihiro Tsukaguchi, Akihiro Tamiya et al. · 2026 · European Journal of Cancer
43. Navigating the waters of immune checkpoint inhibitor pulmonary toxicity
    Rose M. Puthumana, Susan J. Vehar, Abigail L. Koch · 2025 · Journal of Precision Respiratory Medicine
44. Multiple rechallenges with anti-PD-1 immunotherapy in patients with checkpoint inhibitor-related pneumonitis: A report of two cases
    Zheng Yan, Shuna Yao, Junhui Yuan, Yanyan Liu, Zhihua Yao · 2022 · Journal of Oncology Pharmacy Practice
45. Reply to “Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors”
    Jun Fukihara, Koji Sakamoto, Junji Koyama, Takayasu Ito, Shingo Iwano, Masahiro Morise, Masahiro Ogawa, Yasuhiro Kondoh, Tomoki Kimura, Naozumi Hashimoto et al. · 2019 · Clinical Lung Cancer
46. Respiratory Complications
    Vickie R. Shannon, George A. Eapen, Carlos A. Jiménez, Horiana B. Grosu, Rodolfo C. Morice, Lara Bashoura, Ajay Sheshadre, Scott E. Evans, Roberto Adachi, Michael H. Kroll et al. · 2022 · Wiley eBooks
47. Knowledge Mapping of Immune checkpoint inhibitor-related Pneumonitis: A Bibliometric Analysis (2011–2022)
    Qin Qin, Kefei Cao, Yulong Wang · 2023
48. Non-Rheumatic Immune-Related Adverse Events
    Aanika Balaji, Bairavi Shankar, Jarushka Naidoo · 2021 · Springer eBooks
49. Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
    Marianne J Davies, Armand Vincent Russo · 2021 · Current cancer research
50. Immune-mediated pneumonitis: A clinical conundrum in a patient with stage IV lung adenocarcinoma with a dramatic and durable response to checkpoint inhibitor case report
    Ezra Bernstein, Joshua K. Sabari · 2022 · Current Problems in Cancer Case Reports
51. Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors
    Mateusz M. Polaczek, Rutkowski Piotr · 2023 · Springer eBooks
52. Risk factors and clinical outcomes of immune checkpoint inhibitor-related pneumonitis in patients with advanced non-small cell lung cancer：A single center experience
    Ning Wang, Renzhe Xiao, Yulin Liu · 2023 · Research Square
53. Immune Checkpoint Inhibition
    James M. Isaacs, Afreen Idris Shariff, Jeffrey Crawford · 2023 · Springer eBooks
54. Immune Checkpoint Inhibition
    James M. Isaacs, Afreen Idris Shariff, Jeffrey Crawford, Michel Georges Khouri, Meenal Kheterpal, Sarah LeNoir Sammons, Michelle Ferreira, April Wall, Jane E. Onken, Lindsay King et al. · 2024 · Springer eBooks
55. Immune-checkpoint Inhibitors in Anti-cancer Armamentarium: a Double-edged Sword in Risk of Developing Autoimmunity and Immune-related Adverse Effects
    2025 · Frontiers research topics
56. Real-world incidence of pneumonitis in different treatment modalities of advanced non-small cell lung carcinoma
    Justine Henriëtte Cuperus, Hanieh Abedian Kalkhoran, Henk Codrington, Loes E. Visser · 2025 · Lung Cancer
57. The Evaluation of the Oncologic Patient for Drug-Induced Pneumonitis
    Terra C. Swanson, Brent W. Kinder, Joshua M. Clark · 2025 · Seminars in Respiratory and Critical Care Medicine
58. Genetic haplotypes in VWA8, OSBPL6, and ADAMTS9-AS2 are associated with immune-related adverse effects in ICI-treated patients with cancer
    Prithvi Raj, Jialiang Liu, Chengsong Zhu, Carlos Arana, Farjana Jahan Fattah, Hong Mu-Mosley, Benjamin Switzer, Jason Y. Park, Mitchell S. von Itzstein, Edward K. Wakeland et al. · 2025 · Journal for ImmunoTherapy of Cancer
59. CCL18 with an attitude: unlocking the role of macrophage CCL18 in checkpoint inhibitor pneumonitis
    Nathanial J. Tolman, William Bain · 2025 · American Journal of Respiratory Cell and Molecular Biology
60. Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy
    Adam Khorasanchi, Mingjia Li, Songzhu Zhao, Lai Wei, Evelyn G. Goodyear, Kevin Ho, Hamzah Abu‐Sbeih, Austin Secor, Erin Marie Bertino, Peter G. Shields et al. · 2025 · Lung Cancer
61. Additional file 8 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara, Inoue, Yusuke, Hideki Yasui, Masato Karayama, Suzuki, Yuzo, Hironao Hozumi, Kazuki Furuhashi, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Kazuhito Funai et al. · 2024 · Figshare
62. Additional file 4 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara, Inoue, Yusuke, Hideki Yasui, Masato Karayama, Suzuki, Yuzo, Hironao Hozumi, Kazuki Furuhashi, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Kazuhito Funai et al. · 2024 · Figshare
63. Additional file 7 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara, Inoue, Yusuke, Hideki Yasui, Masato Karayama, Suzuki, Yuzo, Hironao Hozumi, Kazuki Furuhashi, Noriyuki Enomoto, Fujisawa, Tomoyuki, Kazuhito Funai et al. · 2024 · Figshare
64. Additional file 3 of Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
    Suzuki, Yuzo, Kazutaka Mori, Aono, Yuya, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi et al. · 2021 · Figshare
65. Additional file 1 of Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis
    Yueyuan Yao, Butuo Li, Ruiting Song, Yang, Linlin, Bing Zou, Wang, Linlin · 2024 · Figshare
66. Additional file 1 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara, Inoue, Yusuke, Hideki Yasui, Masato Karayama, Suzuki, Yuzo, Hironao Hozumi, Kazuki Furuhashi, Noriyuki Enomoto, Fujisawa, Tomoyuki, Kazuhito Funai et al. · 2024 · Figshare
67. Additional file 3 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara, Inoue, Yusuke, Hideki Yasui, Masato Karayama, Suzuki, Yuzo, Hironao Hozumi, Kazuki Furuhashi, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Kazuhito Funai et al. · 2024 · Figshare
68. Additional file 5 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara, Inoue, Yusuke, Hideki Yasui, Masato Karayama, Suzuki, Yuzo, Hironao Hozumi, Kazuki Furuhashi, Noriyuki Enomoto, Fujisawa, Tomoyuki, Kazuhito Funai et al. · 2024 · Figshare
69. Additional file 1 of Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
    Wang, Jingting, Ma, Yan, Haishan Lin, Jing Wang, Cao, Bangwei · 2024 · Figshare
70. Additional file 2 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara, Inoue, Yusuke, Hideki Yasui, Masato Karayama, Suzuki, Yuzo, Hironao Hozumi, Kazuki Furuhashi, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Kazuhito Funai et al. · 2024 · Figshare
71. Additional file 6 of Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara, Inoue, Yusuke, Hideki Yasui, Masato Karayama, Suzuki, Yuzo, Hironao Hozumi, Kazuki Furuhashi, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Kazuhito Funai et al. · 2024 · Figshare
72. Mechanisms of Immunological Toxicity in Cancer Immunotherapy with Checkpoint Inhibitors
    Mateusz M. Polaczek, Rutkowski Piotr · 2025 · Springer eBooks
73. Immune Check Point Inhibitors Associated Toxicities
    Prabalini Rajendram, R. Scott Stephens, Cristina Gutiérrez · 2026 · Springer eBooks
74. Immune-related adverse events between elderly patients with gastrointestinal and lung cancers: A real-world study
    Infong Chan, Lingdong Kong, Bo Jia, Fengxiao Dong, Yuling He, Xumeng Ji, Guomei Ren, Lili Wang, Zhihao Lu, Lin Shen et al. · 2026 · Chinese Medical Journal
75. Survival Outcomes After irAE-Related Nivolumab Discontinuation in mNSCLC: A Multicenter Study
    Ayşegül Merç Çetinkaya, Mehmet Haluk Yücel, Latif Karahan, Mustafa Ersoy, Ahmet Erkan Bilici, M. Erman, Ali Murat Tatlı, Sema Sezgin Goksu · 2026 · Journal of Clinical Medicine
76. Diagnostic and decision-making disparities in precision oncology in thoracic malignancies with interstitial pneumonia: A real-world cohort study
    Yutaro Kimura, Naozumi Hashimoto, Toshikazu Watanabe, Yasuhiro Gotô, Tomoya Horiguchi, Tomohide Souma, Shotaro Okachi, Yuko Oya, Sumito Isogai, Masashi Kondo et al. · 2026 · Respiratory Investigation
77. Efectos adversos inmunorrelacionados como factor predictivo de respuesta en cáncer de pulmón no microcítico en vida real
    Maria Susana Fortes-González, Silvia Vázquez Blanco, Leticia Herrero-Poch, Lucía Santomé Couto, Ana Cristina Cercós-Lletí · 2026 · Farmacia Hospitalaria
78. Five-year prognostic impact of pre-existing interstitial lung disease in non-small cell lung cancer patients treated with anti-PD-1 monotherapy: a retrospective analysis
    Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Kazuhiro Shimomura, Naohiro Watanabe, Yoshitsugu Horio, Yutaka Fujiwara · 2026 · BMC Cancer
79. [Translated article] Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer
    Maria Susana Fortes-González, Silvia Vázquez Blanco, Leticia Herrero-Poch, Lucía Santomé Couto, Ana Cristina Cercós-Lletí · 2026 · Farmacia Hospitalaria
80. DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity
    J. Richard Brewer, Ailin Han, Amin H. Nassar, Elias Bou Farhat, Holly N. Blackburn, Tianli Xiao, Haris Mirza, Walter K. Mowel, Esen Sefik, Saskia Hartner et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
81. LAR/NMLR stratify mortality risk before and after checkpoint inhibitor pneumonitis in NSCLC: multi-state and time-dependent analyses
    Qingwei Zhang, Yijiao Xu, Jianying Liu, Yuting Wang · 2026 · BMC Cancer
82. Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study
    Jie Ju, Z B Liu, Lei Cao, Lina Xia, Pei Zhang, Yanfei Wang · 2026 · Frontiers in Immunology
83. Recruited Monocyte-Derived Macrophages Drive T Cell Inflammation in Immune Checkpoint Inhibitor-Mediated Pneumonitis
    Xiaoran Cui, Renyong Zhi, Xiaoyan Li, Yinming Ji, ZhiSong Hu, Pengfei Cui, Yuhui Qin, Tao Li, Liangliang Wu, Lingxiong Wang et al. · 2026 · 癌症：英文版
84. From inflammatory phenotypes to clinical decisions: a stratified diagnostic and therapeutic framework for CIP
    Shanshan Lin, Wenye Huang, Binlong Zhang, Xiaomin Yang, Haocheng Zhao · 2026 · Frontiers in Immunology
85. Incidence of and risk factors for immune checkpoint inhibitor–related pneumonitis in thoracic malignancies: a prospective multicenter study
    Yoshihiro Kitahara, Naoki Inui, Takafumi Koyauchi, Kazuhiro Asada, Koji Nishimoto, Shun Matsuura, Dai Hashimoto, Takashi Matsui, Masato Fujii, Nao Inami et al. · 2026 · The Oncologist
86. mtDNA Activates AIM2-Mediated PANoptosis in Interstitial Macrophages to Promote Immune Checkpoint Inhibitor Pneumonitis
    Guodong Wu, Xueping Wei, Jiacheng Jiang, Ping Zhu, Tianyuan Xu, Yakun Weng, Long Shuang Huang · 2026 · bioRxiv (Cold Spring Harbor Laboratory)